83 results about "Thyroid Gland Hormone" patented technology

The invention provides a pyridazinone derivative and an application thereof, the pyridazinone derivative with the structure shown in the formula (I) provided by the invention has good activity as a thyroid hormone beta receptor agonist by selecting a specific modification group. The compound can be used for treating and/or preventing diseases caused by thyroid hormone regulation.

The invention provides molecular methods of screening chickens to determine those more likely to have a lean or fat phenotype by identifying the presence of at least one polymorphism in genetic material of a chicken in the thyroid hormone repressible gene (THRG) or its 3′ untranslated region (SEQ ID NO: 1) that is associated with a fat phenotype or a lean phenotype. The invention also provides methods of screening chickens to identify a polymorphism associated with a fat or lean phenotype. The invention further provides oligonucleotide probes and primers useful for detecting the polymorphisms associated with a fat or lean phenotype.

The invention provides a two-hybrid yeast cell for detecting thyrotropic hormone-like/antithyrotropic hormone compounds in a sample and a preparation method thereof, wherein a yeast contains pGBT9-TR yeast expression plasmids and pGAD424-GRIP1 yeast expression plasmids, wherein the pGBT9-TR yeast expression plasmids contain thyroid hormone receptor genes, and the pGAD424-GRIP1 yeast expression plasmids contain thyroid hormone receptor coactivated factor genetic fragments with the sequence of SEQ ID No.2. The invention also provides a bioassay method for detecting the thyrotropic hormone-like/antithyrotropic hormone compounds in the sample. The yeast and the bioassay method greatly improve the sensitivity of the thyrotropic hormone-like/antithyrotropic hormone compounds. The constructed yeast has stable characteristics and is easy to culture and screen; the screening process of the whole thyrotropic hormone-like/antithyrotropic hormone effect is simple to operate; and the required quantity of the sample is small, and the cost is low.

The present invention relates to pharmaceutical compositions comprising a thyroid hormone drug. The invention also relates to processes for the preparation of such compositions.

The invention relates to a thyroid hormone immunochromatographic test strip and a preparation method thereof, and a thyroid hormone immunochromatographic kit. The test strip comprises a substrate, anda sample pad, a marking pad, a detection film and an absorption pad which are arranged on the substrate, wherein the sample pad, the marking pad, the detection film and the absorption pad are sequentially connected from one end to the other end of the substrate; and the marking pad comprises a marking area, the marking area contains an animal thyroid hormone monoclonal antibody marked by fluorescent microspheres and a first complex marked by the fluorescent microspheres; the detection film is provided with a detection area and a quality control area, the detection area is coated with an animal thyroid hormone antigen, the quality control area is coated with a second complex, and the first complex and the second complex can be specifically combined. According to the thyroid hormone immunochromatographic test strip, fluorescence signals are detected by means of an immunoassay analyzer, the detection sensitivity is greatly improved by a photoelectromagnetic signal amplification system, interference of background colors is effectively eliminated, misjudgment of human factors on results is reduced, and the thyroid hormone immunochromatography test strip is safe, simple and rapid to operate and high in sensitivity.

The invention belongs to the field of biomedicines, particularly relates to the field of targeting drugs and more specifically relates to a liver-targeting compound with thyroid hormone receptor stimulating agent characteristics and a pharmaceutical composition of the liver targeting compound. The compound is a compound represented by a formula (1). The compound can be used for treating and/or preventing diseases induced by thyroid hormone regulation disorder and can also be used for effectively reducing lipids in blood plasma and liver cells.

The invention provides a traditional Chinese medicine composition for treating a thyroid nodule and a preparation method. The traditional Chinese medicine composition comprises the preparation raw materials: radix bupleuri, fructus aurantii, rhizoma cyperi, radix ranunculi ternati, ossa draconis, oyster shells, Chuanxiong rhizomes, radix paeoniae rubra, dried tangerine peels, rhizoma pinelliae and radix glycyrrhizae. The traditional Chinese medicine composition is used for treating preliminary-stage thyroid nodule by taking clinical symptoms, nodule size, hormone level and constitution regulation as multiple targets and taking the idea of promoting Qi circulation and dispelling melancholy and regulating Qi and resolving phlegm. The traditional Chinese medicine composition provided by the application can be used for effectively improving the clinical symptoms of a thyroid nodule sufferer, regulating and controlling the level of thyroid hormones, controlling and delaying the disease development of the thyroid nodule, improving the size of the nodule, regulating the global function of the sufferer and changing problems of constitutions prone to the thyroid nodule, thereby performing intervention fundamentally. Furthermore, drug dependence and thyroid function changes caused by long-term oral administration of hormone drugs and risks such as lifetime thyroid hormone drug dependence and nodule recurrence caused after thyroid nodule excision can be avoided to a relatively large extent.

Anguilliformes breeding water contains a thyroid hormone such as thyroxine, and a method for rearing anguilliformes includes a step for administering a thyroid hormone such as thyroxine, wherein the amount of the thyroid hormone to be administered changes as the anguilliforme fingerling changes from a transformation start phase (stage 1) to a transformation final phase (stage 2), and the amount of the thyroid hormone to be administered in the transformation final phase (stage 2) is less than the amount of the thyroid hormone to be administered in the transformation start phase (stage 1).

The present patent relates to a method for qualitative identification and quantitative prediction of thyroid hormone disrupting chemicals base on the interaction between thyroid hormone receptor and co-regulators (coactivator and corepressor).The method identifies chemicals as passive antagonists, active antagonists and agonists by means of co-regulator involved molecular dynamics simulations, and predicts the relative disrupting potencies by use of binding free energy, therefore, may be used for screening of thyroid hormone disruptors among environmental pollutants. Upon more comprehensive consideration of the functioning mechanism of thyroid hormone receptor, the present invention is able to sufficiently identify thyroid hormone disruptors as agonists and antagonists, and gives more accurate prediction of the disrupting potency. Further, since nuclear receptors, just as thyroid hormone receptor, are strongly associated with co-regulators, the method may be expanded to the screening of nuclear receptor mediated endocrine disruptors.

The present invention provides a method for quickly detecting thyroid interferent. It uses the tail of xanopus tadpole of 53-55 stage as test material, and uses thyroid hormone to induce it to be absorbed and shortened, at the same time it makes the testing method undergo the process of exposure treatment, and utilizes the comparison of difference of shortened condition of tail of testing material exposure group and contrast to evaluate the thyroid interference activity.

Disclosed herein are pharmaceutical compositions to treat or prevent obesity, excess or overweight conditions, and metabolic syndrome comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents. Further disclosed herein are methods of treating or preventing obesity, excess or overweight conditions, and metabolic syndrome comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents.

The invention discloses the application of MIT and/or DIT as a thyroid cancer marker and a kit. MIT and DIT are synthetic precursor substances of thyroid hormone T4, and the synthetic precursor substances have stable expression and constant existence in thyroid tissue and have high specificity and effectiveness. According to the invention, conditions that expression quantities of the MIT and the DIT are remarkably different in thyroid cancer tissue and thyroid normal tissue and the expression quantities of the MIT and the DIT in the thyroid cancer tissue are 100-200 times lower than the expression quantities of the MIT and the DIT in the normal tissue are found for the first time. Based on this, the MIT and DIT can be used as biomarkers for thyroid cancer detection, corresponding analysismethods can be used for preparing a thyroid cancer detection kit, and a novel technical means is provided for thyroid cancer detection, diagnosis, treatment and prognosis evaluation. According to theinvention, a thyroid cancer sample collected by a puncture needle can be accurately analyzed, and the purpose of ultra-efficient and high-sensitivity detection of the kit is achieved.

A topical preparation for treating first and second degree burns includes TriAc. The topical preparation preferably includes less than 10 mg of TriAc per 100 ml of pharmaceutical excipient base. In another embodiment, a topical preparation includes TriAc for decreasing cellulite. In this embodiment, the topical preparation is preferably applied only before exercise. In a preferred embodiment, the preparation is applied only intermittently, preferably no more than three times a week, or in amounts sufficient to not downregulate receptor number and become inefficacious.

Disclosed herein are pharmaceutical compositions for the treatment of acquired brain injury (ABI), including traumatic brain injury (TBI) and acute non-traumatic brain injury (ANBI), post-traumatic stress disorder (PTSD), and other degenerative neurological disorders that may or may not be associated with ABI comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the intensity of or reducing the severity of ABI and/or PTSD, the method comprising administering an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

The invention provides a heterocyclic compound with a structure as shown in a formula (I) which is described in the specification, and experimental results show that the heterocyclic compound providedby the invention has good activity as a thyroid hormone beta receptor stimulant and can be used for treating and/or preventing diseases caused by thyroid hormone regulation.

The invention provides application of a thyroid hormone and an analogue thereof in preparation of drugs for treating a sickle-cell disease, and particularly relates to application in regulation and control of zeta-globin gene expression. In the K562 cell differentiation process, the thyroid hormone analogue can specifically and remarkably up-regulate the expression of zeta-globin gene (HBZ) by more than 50 times; and after treatment is carried out in a zebra fish embryo of a model animal by the thyroid hormone and the analogue thereof, the expression of the zeta-globin gene (hbae5) can also bespecifically up-regulated by more than 30-70 times. Therefore, the thyroid hormone and the analogue thereof disclosed by the invention can specifically activate the expression of the zeta-globin gene, namely, the silent zeta-globin gene in the body of a sickle-cell disease patient is reactivated to inhibit sickle hemoglobin S polymerization reaction, the thyroid hormone and the analogue become amethod for preparing the drugs for treating the sickle-cell disease, an economical, safe and effective method is provided for treatment of the sickle-cell disease, and the method can be widely appliedand popularized.